SIC
NTLA icon

Salem Investment Counselors’s Intellia Therapeutics NTLA Stock Holding History

Salem Investment Counselors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$34.5K – 887
2025
Q3 		$34.5K Hold
2,000
– – ﹤0.01% 668
2025
Q2 		$18.8K Hold
2,000
– – ﹤0.01% 733
2025
Q1 		$14.2K Buy
+2,000
New +$20.2K ﹤0.01% 779
2024
Q4 		– Sell
-1,500
Closed -$30.8K – 1254
2024
Q3 		$30.8K Buy
1,500
+250
+20% +$5.76K ﹤0.01% 681
2024
Q2 		$28K Buy
+1,250
New +$29.8K ﹤0.01% 677

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Salem Investment Counselors's NTLA Position: Q4 2025 in Review

Salem Investment Counselors sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 2,000 shares — an estimated $34.5K sold.

Salem Investment Counselors first reported a position in NTLA in Q2 2024 and held it in 5 quarters. The position peaked at $34.5K in Q3 2025. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Salem Investment Counselors reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 2,000 Intellia Therapeutics shares in Q4 2025, an estimated $34.5K.
  • Salem Investment Counselors first reported a position in Intellia Therapeutics in Q2 2024 and held it in 5 quarters.
  • Salem Investment Counselors's Intellia Therapeutics position peaked at $34.5K in Q3 2025.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Salem Investment Counselors's 13F filing for Q4 2025, filed 12 Jan 2026.